PromarkerD test scores show treatment with canagliflozin can lessen risk of diabetic kidney disease

Proteomics International in collaboration with Janssen Research & Development have shown that PromarkerD demonstrates the benefits of canagliflozin and offers potential as a precision diagnostic tool in diabetic kidney disease.

The latest research is published in the international peer-reviewed Journal of Clinical Medicine.

ASX Release